Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomised, Double-blind, Placebo-controlled, 6 Treatment, 4 Period, Incomplete Cross-over Trial to Characterise the 24-hour Lung Function Profiles of Tiotropium + Olodaterol Fixed Dose Combination (2.5/5 mcg, 5/5 mcg), Tiotropium (2.5 mcg, 5 mcg) and Olodaterol (5 mcg) (Oral Inhalation, Delivered by the Respimat Inhaler) After 6 Weeks Once Daily Treatment in Patients With Chronic Obstructive Pulmonary Disease (COPD) [VIVACITO]

Next Previous
X
Search
Trial Profile

Randomised, Double-blind, Placebo-controlled, 6 Treatment, 4 Period, Incomplete Cross-over Trial to Characterise the 24-hour Lung Function Profiles of Tiotropium + Olodaterol Fixed Dose Combination (2.5/5 mcg, 5/5 mcg), Tiotropium (2.5 mcg, 5 mcg) and Olodaterol (5 mcg) (Oral Inhalation, Delivered by the Respimat Inhaler) After 6 Weeks Once Daily Treatment in Patients With Chronic Obstructive Pulmonary Disease (COPD) [VIVACITO]

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 24 Dec 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Olodaterol/tiotropium bromide (Primary) ; Olodaterol; Tiotropium bromide
  • Indications Chronic obstructive pulmonary disease
  • Focus Registrational; Therapeutic Use
  • Acronyms VIVACITO
  • Sponsors Boehringer Ingelheim Pharmaceuticals

    • Most Recent Events

    • 19 Aug 2014 The FDA has accepted an NDA for olodaterol/tiotropium for maintenance therapy for COPD based on results from TOnado-1, TOnado-2 and VIVACITO, according to a Boehringer Ingelheim media release.
    • 02 Jul 2014 According to a Boehringer Ingelheim media release, results from TOnado 1 and 2 as well as other TOviTO programme data are expected to be reported later in 2014.
    • 01 Aug 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top